Kirsten Detrick

Kirsten Detrick is Vice President, Therapeutic Area Commercial Leader for Takeda’s global gastroenterology (GI) portfolio. Her team’s most recent launch was Entyvio (vedolizumab), a biologic treatment for Inflammatory Bowel Disease that was approved in 2014 and is already commercialized in approximately 20 countries worldwide. Entyvio is currently a top 15 drug launch in any category since 2008. It is also the first truly global launch of a biologic at Takeda. Kirsten joined the Takeda team in their Zurich, Switzerland, offices in 2013.

Takeda, Kirsten was with Amgen for over nine years. During her tenure there, she developed marketing strategies for a range of specialty cardiovascular therapeutics across the heart failure and hypercholesterolemia categories; teamed with colleagues to successfully complete three major business development deals with Japanese, French and U.S. partners; led the U.S. launch of Prolia (denosumab), the company’s first biologic to enter the primary care space and held a variety of leadership roles on Enbrel, including Vice President, U.S. Rheumatology Sales and Marketing.